Critical Limb Ischemia Treatment Market By Treatment Approach (Endovascular Revascularization, Surgical Bypass, Hybrid Revascularization, Deep Vein Arterialization, Wound Care & Limb Preservation Therapy); By Product/Device Type (Drug-Coated Balloons, Stents & Drug-Eluting Scaffolds, Specialty Balloons, Atherectomy Systems, Venous Arterialization Systems, Bypass Grafts, Below-the-Knee Revascularization Devices, Limb-Salvage Systems); By Application (Below-the-Knee Arterial Disease, No-Option CLTI, Diabetic Foot Ulcers, Non-Healing Ischemic Wounds, Rest Pain Management, Gangrene & Tissue Loss, Major Amputation Prevention); By End User (Hospitals, Vascular Centers, Specialty Clinics, Ambulatory Surgical Centers, Wound Care Centers); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Critical Limb Ischemia Treatment Market: Below-the-Knee Devices, Limb-Salvage Systems, and Revascularization Evidence Redefine CLTI Care

The Global Critical Limb Ischemia (CLI) Treatment Market was valued at USD 5.72 billion in 2025 and is projected to reach USD 8.87 billion by 2032, expanding at a CAGR of 6.47%.

 

Critical limb ischemia treatment is shifting toward earlier vascular referral, structured limb assessment, below-the-knee revascularization, wound-care coordination, and evidence-backed limb salvage. Chronic limb-threatening ischemia, still widely referred to as critical limb ischemia, represents the most severe form of peripheral artery disease. CDC estimates that about 6.5 million U.S. adults aged 40 and older have PAD, while Global Burden of Disease 2019 data estimated 113 million people aged 40 and older living with PAD worldwide. Severe PAD progression creates recurring demand for vascular testing, endovascular therapy, bypass surgery, hybrid procedures, wound management, antithrombotic therapy, stents, scaffolds, drug-coated balloons, venous arterialization systems, and post-procedure surveillance.

 

CLI carries a higher treatment urgency than routine PAD because rest pain, ulcers, gangrene, infection risk, and tissue loss shorten the window for conservative management. Older epidemiology literature estimated that one year after CLI presentation, 25% of patients were dead, 30% had undergone amputation, and only 45% remained alive with both limbs. Contemporary Medicare evidence still shows a heavy survival burden. The CLIPPER cohort included 1,130,065 fee-for-service Medicare patients diagnosed with CLTI from 2010 to 2019; 20.4% underwent percutaneous or surgical revascularization within 30 days, 3.3% had major amputation within 6 months, 16.7% died within 1 year, and 50.3% died within 5 years. Hospitals and vascular teams are therefore treating CLI as a limb-and-life preservation problem, not only as a peripheral vascular procedure category.

 

Diabetes, Kidney Disease, and Wound Burden Shape the Treatable Population

CLI demand concentrates in patients with advanced atherosclerosis, diabetes, chronic kidney disease, coronary artery disease, smoking history, neuropathy, and non-healing foot wounds. CDC identifies smoking, diabetes, high blood pressure, high cholesterol, atherosclerosis, and age above 60 as key PAD risk factors. In CLI, these risk factors convert into rest pain, ulcers, gangrene, infection, hospitalization, and amputation risk. Vascular specialists, podiatrists, wound-care teams, interventional cardiologists, vascular surgeons, and hospital systems increasingly manage CLI through coordinated limb-preservation pathways.

Medicare evidence confirms that CLI care must work for older, comorbid, and access-sensitive populations. The CLIPPER cohort had a mean age of 75 years, with women representing 48.4% and Black patients representing 14.6%. Treatment pathways built around delayed referral or isolated procedures are poorly matched to this population because many patients need perfusion testing, wound staging, infection control, revascularization decisions, and post-procedure surveillance within the same care cycle.

Readmissions expose the cost pressure behind CLI treatment. A national readmission analysis of 695,782 admissions from 212,241 patients found all-cause readmission rates of 27.1% at 30 days and 56.6% at 6 months, with most readmissions unplanned. A JAMA Network Open analysis noted that CLI hospitalizations cost about USD 4.2 billion annually, with an additional USD 624 million in 30-day readmission cost. Device and procedure adoption therefore depends on more than successful vessel opening. Hospitals need fewer repeat admissions, better wound closure, lower infection burden, and lower major amputation rates.

 

Limb Staging and Anatomy Are Reshaping Procedure Choice 

CLTI treatment decisions are increasingly driven by limb severity and anatomic feasibility rather than by PAD diagnosis alone. Global Vascular Guidelines define CLTI as PAD with rest pain, gangrene, or lower-limb ulceration lasting more than two weeks. This definition captures patients at immediate risk of tissue loss and major amputation. In the Medicare CLIPPER cohort, 3.3% of patients underwent major amputation within 6 months of diagnosis and 16.7% died within 1 year. These outcomes support earlier staging and faster revascularization decisions.

WIfI staging identifies the combined impact of wound burden, ischemia, and foot infection. GLASS assessment identifies the complexity of the target arterial pathway. These frameworks determine whether a patient is suitable for endovascular therapy, bypass surgery, hybrid treatment, deep vein arterialization, or amputation. Patients with severe tissue loss, infection, infrapopliteal occlusion, heavy calcification, poor distal runoff, or no usable vein conduit require more complex treatment pathways. Device demand is therefore concentrated in below-the-knee interventions, vessel preparation, drug-eluting scaffolds, specialty balloons, bypass grafting, and no-option limb-salvage systems.

The 2024 ACC/AHA multisociety PAD guideline recommends revascularization in CLTI to reduce tissue loss, support wound healing, relieve ischemic pain, and preserve a functional limb. For patients with non-healing wounds or gangrene, the guideline supports procedures that restore in-line flow or maximize perfusion to the wound bed. This shifts market value toward technologies that demonstrate wound healing, amputation-free survival, durable patency, and lower repeat intervention rates rather than procedural success alone.

 

Surgical Bypass and Endovascular Therapy Are Competing on Patient Fit

Revascularization strategy remains the main decision point in CLI treatment. Endovascular therapy offers lower procedural invasiveness, shorter recovery potential, and suitability for many high-risk patients. Surgical bypass can provide durable blood flow in selected patients, especially when a usable great saphenous vein is available. Procedure selection is becoming more selective as evidence separates patients who benefit from surgery from those better suited to catheter-based therapy.

BEST-CLI changed the revascularization debate by comparing surgical and endovascular strategies in patients with CLTI and infrainguinal PAD. The trial enrolled 1,830 patients in two parallel cohorts. In patients with adequate great saphenous vein conduit, surgical treatment reduced the incidence of major adverse limb events or death compared with endovascular therapy. In patients without adequate vein conduit, outcomes were more similar between strategies. Surgical bypass therefore retains strong relevance in vein-available patients, while endovascular therapy remains essential for frail patients, limited-conduit cases, complex distal anatomy, and patients for whom open surgery carries higher risk.

CMS has also emphasized the severity of the CLTI treatment population. A 2026 coverage-response article noted that CLTI patients often have diabetes, chronic kidney disease, coronary artery disease, and other complications. CMS also noted that more than 70% of CLTI procedures in a national cohort of adults aged 65 and older were performed inpatient. Reimbursement scrutiny will remain high because repeat procedures, inpatient stays, wound care, infection management, and rehabilitation costs accumulate quickly.

 

Below-the-Knee Devices Are Targeting Restenosis and Repeat Intervention

Below-the-knee revascularization plays a critical role in limb salvage, particularly in patients with chronic limb-threatening ischemia, as infrapopliteal vessel patency is closely associated with wound healing outcomes and the risk of amputation. However, conventional balloon angioplasty remains limited by restenosis and vessel recoil, which can compromise long-term clinical durability.

FDA approved Abbott’s Esprit BTK Everolimus Eluting Resorbable Scaffold System on April 26, 2024 for CLTI. In a 261-patient study, 1-year effectiveness was 75% with Esprit BTK versus 44% without a scaffold. The endpoint included freedom from above-ankle amputation, repeat intervention, and significant restenosis. Major safety events were absent in about 97% of patients.

Three-year LIFE-BTK data published in 2026 showed sustained patency benefit and lower restenosis versus percutaneous transluminal angioplasty. FDA received the 2-year post-approval report on April 22, 2026. These data support scaffold use in selected BTK lesions where repeat intervention risk is high.

Drug-coated balloons and sirolimus-eluting scaffolds remain active development areas. CMS 2026 coding materials identified restenosis and recoil as major barriers in infrapopliteal intervention and included the MicroStent Peripheral Vascular Stent System for a requested October 1, 2026 coding pathway. Adoption will depend on durable patency, lower reintervention, wound healing, and reimbursement support.

 

No-Option CLTI Is Creating a Distinct Limb-Salvage Segment

No-option CLTI patients have no suitable standard endovascular or surgical revascularization route and face high amputation risk. These patients sit outside routine balloon, stent, or bypass pathways. Amputation-free survival, wound healing, pain relief, and quality-of-life recovery matter more than vessel patency alone in this segment.

FDA approved the LimFlow System on September 11, 2023 for CLTI patients who are likely to require amputation and are not good candidates for surgical bypass. The device creates a connection between an artery and a vein to route blood past blocked arteries into the foot. FDA reported 66.1% amputation-free survival at 6 months in a 105-subject study, with wound-healing and quality-of-life improvements in subjects with evaluable images.

Post-approval data are strengthening the evidence base for venous arterialization. FDA’s LimFlow post-approval study page reported that 100 subjects were enrolled in PROMISE III as of August 29, 2025, across 24 sites. Follow-up completion rates were 97.9% at 1 month, 95.5% at 3 months, and 100% at 6 months among eligible follow-ups. No-option devices with prospective post-approval tracking give hospitals a clearer basis for building limb-salvage programs, especially where primary amputation has historically been the default option after failed revascularization.

Deal activity confirms that no-option CLTI is moving into larger medtech portfolios. Inari Medical agreed to acquire LimFlow for up to USD 415 million in 2023, including USD 250 million upfront and up to USD 165 million in milestone payments. Stryker completed its acquisition of Inari Medical in February 2025, giving LimFlow a larger platform for vascular-device distribution, physician training, and hospital-account access. Limb-salvage technology is moving from small-device specialization into broader peripheral vascular commercialization.

 

Cost Pressure Is Raising the Bar for Limb-Salvage Evidence

CLI treatment is expensive because patients often need vascular procedures, wound care, infection management, inpatient admission, repeat imaging, home care, rehabilitation, and long-term cardiovascular management. A population-based JAHA study found follow-up costs per patient-year of about USD 49,700 for endovascular revascularization, USD 49,200 for surgical revascularization, and USD 55,700 for major amputation. Major amputation may appear procedurally definitive, but downstream mortality, rehabilitation, prosthetics, disability, and readmission weaken the economic case for amputation-first care when limb salvage is feasible.

Coverage scrutiny is rising around endovascular PAD procedures. CMS’s 2026 article on endovascular PAD management noted that CLTI patients often present with multiple complications and comorbidities and may warrant inpatient admission. Severe CLTI intervention is therefore treated differently from lower-risk claudication procedures, but providers must document lesion severity, wound status, ischemia, prior therapy, and patient selection carefully. Device suppliers that help hospitals support documentation and outcome tracking will be better positioned than hardware-only competitors.

Readmission data make wound healing and care coordination central to treatment value. A procedure that restores flow but leaves patients cycling through infection, debridement, repeat angioplasty, and hospitalization will face pressure under cost-sensitive care models. Vascular centers are building value through limb-preservation teams, podiatry coordination, diabetic foot surveillance, imaging, wound tracking, and early intervention. Procedure success is increasingly measured by major-amputation avoidance, fewer urgent admissions, and preservation of a functional limb.

 

Regional Adoption Is Being Driven by Disease Burden, Procedure Capacity, and Reimbursement Discipline

The U.S. remains the most commercially advanced CLI treatment market because it combines a large PAD population with established vascular referral networks, Medicare claims infrastructure, FDA device pathways, and high-volume endovascular centers. CDC estimates that 6.5 million U.S. adults aged 40 years and older have PAD. The CLIPPER Medicare cohort included more than 1.13 million patients diagnosed with CLTI between 2010 and 2019. Only 20.4% underwent revascularization within 30 days. Major amputation occurred in 3.3% within 6 months. Mortality reached 16.7% at 1 year and 50.3% at 5 years. These outcomes support demand for earlier intervention, better wound surveillance, and technologies that reduce repeat procedures.

FDA approvals are strengthening the U.S. market for differentiated CLTI devices. Abbott’s Esprit BTK received FDA approval in April 2024 for below-the-knee arteries in CLTI. FDA reported 75% effectiveness at 1 year versus 44% with treatment without a scaffold. LimFlow received FDA approval in September 2023 for no-option CLTI patients at high risk of amputation. FDA reported 66.1% amputation-free survival at 6 months. These products address two high-value segments. Esprit BTK targets infrapopliteal restenosis and recoil. LimFlow targets patients without conventional bypass or endovascular options.

Europe has strong vascular surgery and endovascular capability. Adoption is more dependent on national reimbursement decisions and health technology assessment. BEST-CLI supports surgical bypass in patients with adequate great saphenous vein conduit. This is relevant in European systems where durable limb outcomes and lower reintervention rates influence funding decisions. Endovascular therapy remains important for frail patients, severe calcification, distal disease, and limited conduit availability. European hospitals will favor technologies that show lower major amputation rates, improved wound healing, and reduced repeat intervention.

Asia Pacific has a large untreated PAD and CLTI population. Global Burden of Disease 2019 estimated 113 million people aged 40 years and older were living with PAD worldwide. A substantial share of this burden is concentrated in Asia because of diabetes growth, smoking exposure, aging populations, and delayed vascular diagnosis. Access to vascular specialists remains uneven across the region. This creates demand for lower-cost endovascular therapy, diabetic foot programs, wound-care networks, and referral systems that identify limb-threatening ischemia before tissue loss becomes irreversible.

Japan is becoming an important expansion market for regenerative CLI treatment. In October 2025, Medinet Japan signed an option license agreement with Stempeutics for Stempeucel in CLTI. Japan has advanced regenerative medicine infrastructure and a large elderly population with diabetes, renal disease, and vascular disease. Adoption will depend on local clinical evidence, reimbursement approval, manufacturing standards, and physician confidence in limb-salvage outcomes.

 

Device Suppliers Are Competing on Limb-Salvage Systems, Not Isolated Tools

Abbott strengthened its CLI position through Esprit BTK, especially in below-the-knee infrapopliteal disease where restenosis and repeat intervention limit standard angioplasty. FDA approval tied to randomized evidence and post-approval follow-up gives the product stronger credibility than devices supported mainly by extrapolated PAD data. Sustained patency, wound outcomes, and reintervention data will decide whether hospitals use resorbable scaffolding broadly or reserve it for selected BTK lesions.

Stryker’s entry through Inari and LimFlow adds a no-option limb-salvage route to its vascular presence. LimFlow does not directly compete with routine angioplasty or bypass because it targets patients who lack conventional revascularization options and face amputation. Adoption depends on physician training, patient referral, wound-care integration, and center selection. Complex no-option CLTI devices need procedural ecosystems, not only product availability.

Peripheral vascular suppliers are competing for below-the-knee procedure share through drug-coated balloons, specialty balloons, scaffolds, stents, atherectomy, and adjunctive vessel-preparation tools. Stronger competitors will produce evidence in CLTI-specific patients rather than relying on general PAD performance. Vascular teams and payers will prioritize limb salvage, amputation-free survival, wound healing, patency, lower reintervention, manageable complications, and durable functional benefit.

Stempeutics and Medinet represent a separate route through regenerative medicine. Stempeucel’s India approval and Japan licensing pathway create an Asia-led cell-therapy signal, but the category remains evidence-sensitive. Regenerative products must prove value where revascularization is not possible or insufficient, rather than relying on novelty as the main adoption argument.

 

Adoption Outlook

CLI treatment is increasingly being positioned as an integrated limb-salvage care model rather than a series of standalone vascular interventions. The broader prevalence of peripheral artery disease creates a substantial at-risk population, while chronic limb-threatening ischemia translates this burden into immediate clinical demand for vascular assessment, revascularization, wound care, infection management, and amputation prevention. Medicare-based evidence further highlights the clinical and economic urgency of this patient population, with CLIPPER data showing that one in six patients with CLTI died within one year, and nearly half died within five years.

Below-the-knee intervention represents one of the most important near-term opportunities within the device landscape, as restoration of foot perfusion, wound healing potential, and restenosis management are directly linked to limb-salvage outcomes. Abbott’s Esprit BTK has strengthened this segment by introducing an FDA-approved scaffold platform supported by randomized clinical evidence and ongoing post-approval surveillance. LimFlow has expanded treatment possibilities for no-option CLTI patients by offering a limb-salvage approach for individuals who may otherwise progress toward major amputation. At the same time, findings from BEST-CLI reinforce the continued role of bypass surgery in patients with a suitable great saphenous vein, ensuring that CLI treatment remains a balanced field across both surgical and endovascular strategies.

Diagnosis rates, vascular referral timing, inpatient versus outpatient procedure mix, 30-day and 6-month readmissions, major amputation rates, amputation-free survival, BTK patency, wound-healing outcomes, post-approval device data, Medicare coverage decisions, and coding pathways will decide adoption. Companies that connect procedure success with fewer amputations, fewer repeat admissions, stronger wound closure, and clearer reimbursement documentation will have stronger positioning than suppliers selling devices without limb-salvage evidence.

 

Critical Limb Ischemia (CLI) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.72 Billion
Revenue Forecast in 2032	USD 8.87 Billion
Overall Growth Rate	CAGR of 6.47% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Approach, By Product/Device Type, By Application, By End User, By Geography
By Treatment Approach	Endovascular Revascularization, Surgical Bypass, Hybrid Revascularization, Deep Vein Arterialization, Wound Care & Limb Preservation Therapy
By Product/Device Type	Drug-Coated Balloons, Stents & Drug-Eluting Scaffolds, Specialty Balloons, Atherectomy Systems, Venous Arterialization Systems, Bypass Grafts, Below-the-Knee Revascularization Devices, Limb-Salvage Systems
By Application	Below-the-Knee Arterial Disease, No-Option CLTI, Diabetic Foot Ulcers, Non-Healing Ischemic Wounds, Rest Pain Management, Gangrene & Tissue Loss, Major Amputation Prevention
By End User	Hospitals, Vascular Centers, Specialty Clinics, Ambulatory Surgical Centers, Wound Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising prevalence of peripheral artery disease and diabetes-related vascular complications Increasing focus on limb preservation Growth of below-the-knee revascularization technologies
Customization Option	Available upon request